Apoptosis in multiple sclerosis - Etiopathogenetic relevance and perspectives for new therapeutic strategies [Apoptose bei multipler sklerose. Atiopathogenetische relevanz und perspektiven fur neue therapeutische strategien]

被引：0
作者：
Aktas O. [1 ]
Wendling U. [1 ]
Zschenderlein R. [1 ]
Zipp F. [1 ]
机构：
[1] Neurologische Klinik und Poliklinik, Medizinische Fakultät der Humboldt, Universität Berlin
来源：
Der Nervenarzt | 2000年 / 71卷 / 10期
关键词：
Apoptosis; CD95; Immunopathogenesis; Multiple sclerosis; TNF;
D O I：
10.1007/s001150050664
中图分类号：
学科分类号：
摘要：
Apoptosis, or programmed cell death, is a physiological cell suicide program mainly leading to selective elimination of useless cells. This mechanism is important for the homeostasis of the immune system and presumably plays a two-sided role in the pathogenesis of multiple sclerosis (MS). On the one hand, evidence has been provided that impaired apoptosis might result in increased numbers or persistence of activated myelin-specific T cells, thus inducing the pathophysiologic processes in MS. On the other hand, local tissue damage might involve apoptosis of glial and neuronal cells and lead to the clinical symptoms. Here, an overview is presented on the current knowledge of the role of apoptosis in the pathogenesis of MS, and implications for related therapeutic strategies are discussed.
引用
收藏
页码：767 / 773
页数：6
相关论文
共 38 条
[11]  
Dowling P., Ming X., Raval S., Et al., Up-regulated p75NTR neurotrophin receptor on glial cells in MS plaques, Neurology, 53, pp. 1676-1682, (1999)
[12]  
Dowling P., Shang G., Raval S., Menonna J., Cook S., Husar W., Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain, J Exp Med, 184, pp. 1513-1518, (1996)
[13]  
Dorr J., Wendling U., Grieger U., Walczak H., Krammer P.H., Nitsch R., Bechmann I., Zipp F., (2000)
[14]  
Drappa J., Vaishnaw A.K., Sullivan K.E., Chu J.L., Elkon K.B., Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity, N Engl J Med, 335, pp. 1643-1649, (1996)
[15]  
Elliott E.A., McFarland H.F., Nye S.H., Et al., Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein, J Clin Invest, 98, pp. 1602-1612, (1996)
[16]  
Gold R., Hartung H.-P., Lassmann H., T-cell apoptosis in autoimmune diseases: Termination of inflammation in the nervous system and other sites with specialized immunedefense mechanisms, Trends Neurosci, 20, pp. 399-404, (1997)
[17]  
Hoffmann V., Rieks M., Juschka M., Et al., Simultaneous increase in the percentage of apoptotic T helper cells and of activated T cells in patients with RRMS during therapy with Copaxone®, Mult Scler, 5, SUPPL. 1, (1999)
[18]  
Kaser A., Deisenhammer F., Berger T., Tilg H., Interferon beta-1b augments activation-induced T-cell death in multiple sclerosis patients, Lancet, 353, pp. 1413-1414, (1999)
[19]  
Kerschensteiner M., Gallmeier E., Behrens L., Et al., Activated human T cells,B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: A neuroprotective role of inflammation?, J Exp Med, 189, pp. 865-870, (1999)
[20]  
Macchi B., Matteucci C., Nocentini U., Caltagirone C., Mastino A., Impaired apoptosis in mitogen-stimulated lymphocytes of patients with multiple sclerosis, Neuroreport, 10, pp. 399-402, (1999)
1234